This study aimed to evaluate the clinical characteristics of PD-1/PD-L1 inhibitor–related PNS and the prognostic impact of antibody subtypes, with the goal of enabling pre-treatment risk warning. The gene discussed is PDCD1; the disease is paraneoplastic neurologic syndrome.